Our research on misfolded proteins was inspired by Prof. Kazutoshi Mori, who in 1993 published about the unfolded protein response (UPR) and endoplasmic reticulum stress, simultaneously reported by Dr. Peter Walter (buckinstitute.org/lab/walter…), and both were recognized by Albert Lasker Award in 2014 (pmc.ncbi.nlm.nih.gov/article…). Prof. Mori delivered plenary lecture in NCRM NICHE 2021 (ncrmniche.org/ncrmniche2021/…), on how misfolded proteins are handled when sensed by the cellular mechanisms (kuias.kyoto-u.ac.jp/e/profil…). One such misfolded alpha-synuclein, its aggregation and correlation to Lewy bodies in Parkinson's disease and Dementia was reported by Prof. Michel Goedert and Prof. Maria Grazia Spillantini, (nature.com/articles/42166), and the development of SH-SY5Y cell lines which when induced, produce misfolded alpha-synuclein reported by Biedler et al in 1978 (aacrjournals.org/cancerres/a…) further fueled the research of ours. We have analyzed on how using gut microbiome, such alpha-synuclein misfolding and the following gut-brain axis propagation of prions, their accumulation as Lewy bodies could be managed (doi.org/10.1080/14796708.202…), after beneficially modifying the same by correcting gut dysbiosis in a clinical study (pubmed.ncbi.nlm.nih.gov/3609…). In the NCRM NICHE 2026 on the 11th October 2026 Prof. Muralidhar Hegde will deliver a plenary talk titled “Development of SH-SY5Y cell lines and its significance in addressing diseases originating due to protein-misfolding at cellular level”. For registration please click: us06web.zoom.us/webinar/regi…. @SpillantiniLab @MichelGoed @CellBiologyUCL @nyuniversity @UCSF @MethodistHosp @GMFHx @ParkinsonDotOrg @lbsorg @LBDAssoc @DementiaUK #NCRM #NCRMNICHE #Alphasyn

Festigel as a cell transplant delivery agent in dentistry: Regeneration of bony defects due to periodontal disease is a major challenge. The team led by Seshadri et al., used autologous bone marrow mononuclear cells (BMMNCs) embedded in a thermo-reversible gelation polymer: Festigel for periodontal regeneration in a 23- year old female patient which yielded a significant beneficial outcome of bone healing and sustained for long in a three years follow-up. In a case of periodontitis (class IV gingival recession), with probing pocket depth (PPD) of 5 mm and 6 mm in relation to mandibular lateral and central incisors respectively, and clinical attachment level (CAL) of 13 mm, correlated with radiographic evidence of severe horizontal bone loss extending up to the apex of mandibular incisor, after debridement, the defect was implanted with BMMNCs impregnated in Festigel as a carrier for cell transplantation. At six months, significant improvement with the clinical parameters: PPD had reduced to 2 mm, clinical attachment level had improved by 6 mm. At 36 months, the radiograph revealed bone regeneration with improvement in vertical and horizontal bone height. (pubmed.ncbi.nlm.nih.gov/2469…) @DentalSaudi @orthodo @orthopracticeus @OrthoProducts @PetroverOrtho @DentistryToday @dentaladvisor @pmdcofficial @GreatLakeDental @Dentaltown @saudiperio @Yuyescongreso #celltransplant #celldelivery #festigel #periodontics

Congratulations to the Madurai Medical College – Dept of Urology team for hosting the TAPASUCON 2026; kickstarted with a workshop covering a wide range of surgical procedures, both complex and innovative by experts from all over. Thanks to Dr.Suryaprakash for demonstrating and sharing his experiences of BHES-HAUS, one-step cell therapy for male urethral stricture, ably assisted by Medi Nippon – NCRM team on handling of Festigel, the endotoxin-excess-free polymer scaffold. The advantages of epithelial cell engraftment in our studies covering the earlier two-step BEES-HAUS and that in BHES-HAUS in comparison with historical data of other management approaches including DVIU, Balloon Dilatations in terms of Q-Max – peak flow rate has been published in the Journal Bladder (doi.org/10.14440/bladder.037…), reiterates, how BHES-HAUS could become an indispensable tool to give patients with male urethral stricture, a long-term CIC and disease recurrence free good quality of Life. #urethralstricture #tapasucon #bheshaus #celltherapy #festigel @UrologyTimes @EurUrolFocus @StanfordUrology @EUplatinum @WVU_Urology @NatureMedicine @WakeForest @UrokulHospital @suryaprakashuro @asukamaru513 @cellseed @OptilumeDCB @laborie

BHES-HAUS one-step, autologous buccal cell therapy for male urethral stricture; Dr.Suryaprakash, Director of SUN Institute of Urology, Lead author of the study presents the exciting data with CIC- free QoL and high Qmax as an outcome in American Urology Association meeting (AUA 2026) at Washington DC. Excerpts of his presentation with answers to questions on suitable case selection and follow-up clinical outcome in this video: youtube.com/watch?v=Mtc0SqlJ… @UrologyTimes @EurUrolFocus @EurUrolOncol @StanfordUrology @urotoday @VaibhavModgil @NaturePortfolio @UofTIMS @WakeForest @TERMCevent @CellMuko @UrokulHospital #bheshaus #urethralstricture #celltherapy #regenerativemedicine #urology

Three novel healthcare solutions from Japan to be presented on 21 Aug: 0800 AM~ Japan time [US time: August 20, 2026, 4pm–5pm PDT / 7pm-8pm EDT] by GN Corporation jointly with SMC lab, Japan. Many novel technologies available in Japan remain relatively unknown outside, despite their significant potential in healthcare. Past two decades, GN Corporation has established a unique translational research ecosystem of identifying those promising technologies from Japan and develop clinically applicable solutions through interdisciplinary research. This presentation highlights three successful healthcare innovations: • Innovation 1: Solution in urology for male urethral stricture using a tissue engineering technology: BEES-HAUS & BHES-HAUS; With Two Bil. $ global market • Innovation 2: Unravelling the immune modulation potential of a food supplement to make it a drug-adjuvant for a rare disease: DMD • Innovation 3: Clinical translation of a bio-inert implant in a suitable rare disease Parry-Romberg Syndrome: STAR-MING; Holding Four ~ Six Bil. $ global market potential Registration URL: events.teams.microsoft.com/e… @JNJNews @JNJInnovation @Medtronic @AbbottNews @Stryker @bostonsci @MerilLife @stempeutic @BIOTRONIK_US @CochlearGlobal @OrthofixMedical @Nuvasive @TeRuMoJapan @terumo_jp @MicroPort @CookMedical @WLGore @WLGoreMedical @NobelpharmaUS @DentsplySirona @SonovaGroup @OsstemImplantUK @OsstemKMDental @AlconEyeCare @CONMED_Corp @conmed @CorinMedical #bheshaus #urethralstricture #celltherapy #starming #breastimplant #facialfiller

Our hearts and prayers are with the people of Kumamoto city at this hard times, after a Mag 7.1 earthquake on 28, July, 2026. Thankfully remember the city, which hosted the International Society of Experimental Hematology 2025 Annual meeting. @kumamotocity_ #令和8年熊本地震 @earthquake_jp @NewEarthquake @EHA_Hematology @ISEHSociety @NCS_Earthquake @SeismoSocietyAm @earthquakeinf @iilmranchi @iilmjhr @emaPichilemu

The Fujio Cup Quiz (FCQ), to our knowledge, the only "Active-Knowledge-Gaining" event in the domain of Stem Cells & Regenerative Medicine, happening every year since 2006, has crossed several milestones viz., >> Participation from scholars of 23 countries >> With representation from 186 Institutes >> By more than 3600 scholars from varied specialties Will be held for the 21st time during NCRM NICHE 2026 on the 11th October 2026; The FCQ registration closes on the 30th July, 2026; Registration is now open in: ncrmniche.org/ncrmniche2026/…. @SaveethaSEC @SIMATS_Univ @aiims_newdelhi @aiims_rpr @kluniversity @SRIHER_Official @SRM_UNIVERSITY @SRMUAP @ShivNadarUniv @presiuniv @ajitpremjii @azimpremjiuniv @iiscbangalore @OffCMCVellore @MAHE_Manipal #ncrmniche #fujiocupquiz #stemcells #regenerativemedicine

Quiz on stem cells and regenerative medicine: The Fujio Cup Quiz 21st Edition in NCRM NICHE 2026; Registration deadline: 30, July, 2026; chennaipatrika.com/post/quiz… #quiz #stemcells #regenerativemedicine #fujiocupquiz #ncrmniche

Connecting Japanese technologies to Indian clinical skills. Interview broadcasted in Thanthi TV (Tamil) The interview explains the potential synergy between India and Japan; with technically qualified manpower India has, if the hi-tech technologies of Japan could come together, that will yield several solutions not only to both the countries but to the global society as earlier demonstrated by the GN Corp-NCRM-MediNippon team of Tissue engineering basic technology in cornea which yielded novel cell therapy technology for male urethral stricture which through Indo-Japan collaboration was later tech-transferred from India to Japan one of the first of its kind in the history. 🎥 Watch the interview: youtube.com/watch?v=uUc4jbUT… 📷YouTube #IndoJapan #RegenerativeMedicine #CellTherapy #TechnologyTransfer #Innovation #Healthcare #TissueEngineering #ClinicalTranslation #MedicalResearch #GNCorporation #NCRM #MediNippon #GlobalHealthcare #ThanthiTV #Collaboration #ScienceForSociety

As we recently celebrated the birthday of Prof. Yoshikazu Kurosawa, the most significant contribution everyone reminisced was his publication in 1981 in Nature titled “Identification of D segments of immunoglobulin heavy-chain genes and their rearrangement in T lymphocytes” (nature.com/articles/290565a0) which was gratefully acknowledged by Prof. Susumu Tonegawa in his Nobel Prize for Medicine Lecture, in 1987 (nobelprize.org/uploads/2018/…). Subsequently, we recollected his visit to NCRM, Chennai, India (ncrm.org) in 2010 and his lecture on “Antibody based novel approach to cancer treatment, Present and Future” which was organized by Dr. Pushkala Subramanian, the present Vice Chancellor of The Tamil Nadu Dr MGR Medical University, who was then the Professor and Head of the Department of Immunology. Time flies, Memories remain; Thanks to Dr. Gene Kurosawa for joining us, as he ceaselessly pursues advanced research on the footsteps of Prof. Yoshikazu Kurosawa on antibody based approaches to manage emerging infectious diseases. Miles to Go before we sleep! @infdisease_news @Antibodies_MDPI @NobelPrize @NobelPeaceOslo @ImmunologyAAI @ImmunoPodcast @ImmunityCP @immunedeficienC @UHN @FHU_PR @Immune_News #ncrm #immunology #nobelprize #antibodies #mab

Thanking all those who joined the presentation on Buccal Epithelium Hashed and Encapsulated in Scaffold – Hybrid Approach to Urethral Stricture (BHES-HAUS) clinical study outcome at the AUA 2026 in Washington DC, USA. Abstract available at auajournals.org/doi/abs/10.1… BHES-HAUS: Major takeaways: • Patient comfort – BHES-HAUS is safe and a single-sitting procedure. • Physician convenience – BHES-HAUS is a less-invasive endoscopic procedure that can be done in any urology setup. • Procedural simplicity – No laboratory-based cell culture or transportation is needed. • Proven safety & Clinical efficacy: In all 15 patients who underwent BHES-HAUS, safety with efficacy shown by recurrence-free outcomes and no need for self-intermittent catheterization in 73.3% of the patients. BHES-HAUS study included patients who had undergone prior procedures viz., DVIU, and BMG plasty, whose failure had resulted in stricture recurrence and those with post-TURP stricture. Poster presented in AUA 2026 can be viewed at: university.auanet.org/poster… Special thanks to the key people instrumental in reaching these heights, who themselves could join: Dr. Senthil Kumar Rajappa, who did the cell culture work for the Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture (BEES‐HAUS) study in India and Japan, whose simplified form is BHES-HAUS; Prof. Suryaprakash Vaddi, whose brainchild was BEES-HAUS, followed by BHES-HAUS; Prof. Dmitriy Nikolavsky, whose work inspired us towards simplifying. Special appreciation and acknowledgement to Prof. Akio Horiguchi, whose validation of BEES-HAUS in animal studies to prove buccal cell engraftment is the first of its kind in the world. It is to be noted that Dr. Suryaprakash proved the clinical efficacy and engraftment for BEES-HAUS, followed by Prof. Horiguchi’s clinical application in Japan. @asukamaru513 @suryaprakashuro @UroRecon @UrologyTimes @WVU_Urology @BURSTurology @UMNUrology @EurUrolFocus @urotoday @nyuniversity @UHN @UofT @Cambridge_Uni @UniofOxford @EurUrolOncol @UrowebESU @UrowebESU @Uroweb @CleClinicUro @MayoUrology @UclaUrology @NM_Urology @bradyresidency @MGHUrology @VUMCurology @JEFFUrology @bcm_urology @VattikutiRobotx @VattikutiUrol @UroAcademic @UrologyCareFdn @WakeForestGURS @RoboUro #AUA2026 #Urology #UrethralStricture #Endourology #ReconstructiveUrology #RegenerativeMedicine #TissueEngineering #ClinicalInnovation #TranslationalResearch #BHESHAUS #BEESHAUS #IndiaJapanCollaboration #celltherapy

>> 再生医療における画期的なBEES-HAUS細胞療法（パラクリン効果と細胞の定着による尿道狭窄症治療）を簡略化したBHES-HAUSの臨床結果をAUA 2026で発表 (linkedin.com/pulse/simplifie…) >> Un'impresa pionieristica nel campo della medicina rigenerativa: la terapia cellulare BEES-HAUS: effetto paracrino e attecchimento cellulare consentono assieme di guarire la stenosi uretrale. I risultati della versione semplificata BHES-HAUS ... >> Avance pionero en medicina regenerativa, la terapia celular BEES-HAUS: El efecto paracrino y el injerto celular se combinan para reparar la estenosis uretral. Los resultados de su versión simplificada, BHES-HAUS, se presentarán en la AUA 2026 >> Eine bahnbrechende Leistung in der regenerativen Medizin: die BEES-HAUS-Zelltherapie – parakriner Effekt und Zellansiedlung heilen gemeinsam die Harnröhrenstriktur. Die Ergebnisse der vereinfachten Version, BHES-HAUS, werden auf der AUA 2026 ... >> Une avancée majeure en médecine régénérative, la thérapie cellulaire BEES-HAUS : effet paracrine et prise de greffe cellulaire, deux mécanismes qui, combinés, permettent de soigner la sténose urétrale. Les résultats de sa version simplifiée, ... >> 再生医学的重大突破BEES-HAUS细胞疗法：旁分泌效应与细胞嫁接，以及修复尿道狭窄。其简化版BHES-HAUS的结果将在AUA 2026上发布

Simplified cell therapy approach: The BHES-HAUS, for male urethral stricture, based on the principles of BEES-HAUS (doi.org/10.3389/fruro.2025.1…). Following the clinically successful outcome of BEES-HAUS cell therapy for male urethral stricture, its pre-clinical proof of engraftment of transplanted buccal mucosal epithelial cells with morphological and immuno-histochemical evidence on the site of urethrotomy (ncrm.org/myth/beeshaus/), restoring integrity of urothelium, preventing exposure of urine to the sub-urothelial tissue triggering spongiofibrosis, thus preventing stricture recurrence, a further simplified version BHES-HAUS has been undertaken as a clinical study (ncrm.org/myth/bheshaus/). In BHES-HAUS, the buccal tissue is hashed into fine tissue bits in the operation room itself and immediately transplanted after mixing with Festigel scaffold, in one sitting without need for a laboratory cell processing or in vitro expansion. Needless to say that there is no need for transportation of the tissue from the patient to a central lab for cell culture and then return transport of the cells to the hospital for transplantation. The patient also doesn't have to undergo two procedures at a gap of few weeks as the BHES-HAUS can be accomplished in a single sitting. The encouraging outcome of BHES-HAUS clinical study will be presented in the American Urological Association Annual meeting 2026 in Washington DC, USA on the 17th May 2026 (auajournals.org/doi/abs/10.1…). More details on the BHES-HAUS procedure with a comparison with BEES-HAUS is available in the URL: ncrm.org/myth/bheshaus/, and the procedure as a short video clip is available in: youtube.com/watch?v=QZpIeiad….

MediNippon Healthcare Pvt Ltd (Indian subsidiary of GN Corp, Japan) supports Create Medic - Japan’s successful entry into the Indian market; From market survey to successful sales following CDSCO approval in a phased manner (ncrm.org/media/pr17apr26.htm) ジーエヌコーポレーションのインド法人メディニッポン・ヘルスケアの支援により、インド市場への参入を進めてきたクリエートメディック株式会社が、4月15日チェンナイ市にて、インド法人 クリエートメディック・インディアの開所式を行いました。 在チェンナイ日本総領事を主賓に迎えた同式には、日印の文化団体、商工会議所、及び金融機関の関係者が出席しました。(minyu-net.com/release/prwire…) thehindu.com/news/cities/che… timesofindia.indiatimes.com/… @Europlaz @FollowCII @ficci_india @IndoJapanExpo @IndoJapanGujrat @IndoJapan_01 @IndianEmbTokyo @JapanConsul @JPN_PMO @JapanGov @JETRO_info #medinippon #gncorpjapan #indojapan @CII4Health

Registration OPEN for XXI Edition of Fujio Cup Quiz; An active knowledge gaining event in the domain of stem cells and regenerative medicine as a part of NCRM NICHE 2026, the 21st Inaugural commemorative anniversary; Every year in October since 2006 (ncrmniche.org/ncrmniche2026/…) @SRIHER_Official @SRMC_official @bvvinmec @DHBKHN_HUST @PhenikaaU @UofT @UHN @TokyoUniv2017 @TUS_PR_en @waseda_univ @Harvard @HarvardHealth @Princeton @nyuniversity @kluniversity @SRM_UNIVERSITY @MPFNeuro @MP_Innovation @univ_indonesia @BrainCanada @UniofOxford @unpad @Cambridge_Uni @CambridgeInt #stemcells #regenerativemedicine #quiz #cornea #fujiocupquiz #ncrmniche #gncorporation #ncrm

Implications of gut microbiome in Multiple Sclerosis, proven by MS like symptoms getting triggered in transgenic mice after transplanting GM (Lachnospiraceae) of MS twins into those mice (pubmed.ncbi.nlm.nih.gov/4025…); In Duchenne Muscular Dystrophy we have documented a safe intervention, yielding favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation: (doi.org/10.1136/bmjnph-2023-…) @DuchenneDay @worldduchenne @destroydisease @defeatduchenne @Laima43899899 @mssocietyindia @1capplegate #multiplesclerosis #duchenne #musculardystrophy